Meta-analysis of 5 studies showed a statistically significant reduction in the relative risk of death due to cardiovascular disease among patients treated with SGLT2 inhibitors compared to patients not treated with SGLT2 inhibitors (RR = 0.81; 95% CI: 0.66–1.00; P = 0.05; I2 = 0%) (Figure 7). This evidence concerns the gene SLC5A2 and cardiovascular disorder.